CANNabinoid Drug Interaction Review (CANN-DIR™)
Abstract Non-prescription cannabidiol (CBD) and medical marijuana (cannabis) currently do not have US Food and Drug Administration (FDA)-approved prescribing information…
Abstract Non-prescription cannabidiol (CBD) and medical marijuana (cannabis) currently do not have US Food and Drug Administration (FDA)-approved prescribing information…
Abstract The current approach to equine anti-doping is focused on the targeted detection of prohibited substances. However, as new substances…
Abstract The control of neuropathic pain is a leading challenge in modern medicine. Traditional medicine has, for a long time,…
Abstract The use of illicit and non-illicit substances is widespread in suicides. The toxicological data may help in understanding the…
Abstract Background: Preclinical research suggests that cannabidiol (CBD) may have therapeutic potential in pathological anxiety. Dosing guidelines to inform future…
Abstract Introduction: The IASP ICD-11 chronic primary pain (CPP) definition includes 19 different painful conditions. In recent years, interest in…
Abstract BACKGROUND: Alcohol and marijuana are commonly used by young adults, and use of both substances, particularly at the same…
Abstract Introduction: Rates of perinatal cannabis use are rising, despite clinical evidence about the potential for harm. Accordingly, pregnant and…
Abstract Introduction: Patients with head and neck cancer (HNC) are usually confronted with functional changes due to the malignancy itself…
Abstract Enriched enrollment randomized withdrawal (EERW) pain trials are designed to include only responders with considerable pain relief without unacceptable…